Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study...( Test confirms antiplatelet effectiven...),Health

Test confirms antiplatelet effectiveness of aspirin in new super pill

ORLANDO, Fla. and DENVER, March 31 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX) announced today that its AspirinWorks Test was used by investigators in The Indian POLYCAP Study (TIPS) to help determine patients' response to aspirin and/or statin therapy.

The TIPS trial examined the effect of combinations of aspirin, statin and three blood-pressure-lowering drugs on blood pressure, lipids, heart rate and urinary 11-dehydrohtromboxane B2 (11dTxB2) as measured by the AspirinWorks Test in more than 2,000 individuals.

Results of the randomized, controlled, double-blind study were presented as a late breaking clinical trial March 30 at the American College of Cardiology (ACC) 58th Annual Scientific Sessions in Orlando, Fla. Corgenix is exhibiting its test in Booth No. 1162 during ACC.09.

Overall results showed that the single combination pill was about as effective as taking the five drugs individually and was well tolerated. Trial results also showed that randomization to aspirin therapy resulted in a reduction in 11dTxB2, validating the findings of the previous CHARISMA trial.

"The use of the AspirinWorks Test in this large, groundbreaking trial demonstrates the value of understanding a patient's individual response to aspirin, and the ability of our test to accurately and consistently determine that response," said Gordon Ens, Corgenix Director of Clinical Affairs.

The TIPS trial is the largest to date to test the theory that a single, low-cost, easy-to-take "super pill" can be used to reduce cardiovascular risk across a large population as effectively as several individual pills.

The AspirinWorks Test measures urinary 11dhTxB2, identified in the previously published CHARISMA trial as an independent predictor of risk modifiable by asp
'/>"/>